GU Ventures
GU Ventures, established in 1995 and based in Gothenburg, Sweden, is an accelerator firm dedicated to supporting projects and companies emerging from the University of Gothenburg. Wholly owned by the Swedish state and managed by the university since 1998, GU Ventures collaborates closely with the University of Gothenburg's Research and Innovation Office as well as various local innovation partners. The firm focuses on the commercialization of research and expertise, emphasizing business ideas that demonstrate commercial viability and address customer needs. By nurturing companies primarily in the life sciences and technology sectors, GU Ventures aims to foster successful businesses that can achieve profitability and contribute positively to regional growth. The overarching goal is to generate beneficial knowledge and capital returns to the University of Gothenburg while promoting the application of research to enhance societal well-being through new products and services.
Thioredoxin Systems
Series A in 2024
Thioredoxin Systems is focused on developing an innovative antibiotic regimen specifically aimed at treating complicated urinary tract infections. The company utilizes a patented combination of ebselen and silver, which is effective against a wide range of multi-drug resistant bacteria. This technology serves multiple purposes, functioning as an antiseptic and antibacterial agent in food production, as well as a medicinal product. By employing this approach, Thioredoxin Systems aims to assist medical professionals in slowing the progression of multi-drug resistance and preventing the development of resistance to antibiotics.
Pretzel Therapeutics
Series A in 2022
Pretzel Therapeutics is a biotechnology company focused on developing therapies for mitochondrial dysfunction. Founded by leading experts in mitochondrial biology, the company aims to create innovative treatments that address the underlying causes of mitochondrial issues. By leveraging a comprehensive understanding of mitochondrial mechanisms, Pretzel Therapeutics seeks to reverse dysfunction at its roots, potentially providing effective solutions for patients suffering from a range of conditions, including those related to aging. The company's name reflects its scientific focus on the mitochondrion, which is characterized by its unique and highly folded inner membrane, distinguishing it from other organelles in the body.
Profundus Imaging
Seed Round in 2021
Profundus AB, based in Gothenburg, Sweden, specializes in the research and development of advanced imaging technology for retinal diagnostics. The company is developing a proof-of-concept prototype for a novel fundus camera that utilizes adaptive optics, a technology originally designed for terrestrial telescopes. This innovative approach significantly enhances imaging resolution, offering 7-10 times greater clarity than conventional devices while covering a larger area of the retina. The primary goal of Profundus AB is to create a clinical tool that aids in the diagnosis of retinal diseases by visualizing subclinical changes that may otherwise go unnoticed.
OnDosis
Seed Round in 2020
OnDosis is a company focused on transforming medication delivery through its proprietary technology, which allows for flexible and individualized dosing of oral medicines formulated as micro units. The company aims to enhance disease management, support patient adherence, and improve convenience for individuals with conditions such as ADHD, pain management, and organ transplant immunosuppression. By offering improved dosing options, OnDosis seeks to address significant healthcare burdens and ultimately enhance patient outcomes. Founded in 2017 and headquartered in Gothenburg, Sweden, OnDosis emerged from research initiated at AstraZeneca and is supported by strategic partnerships in formulation, device development, regulatory affairs, and business development. The company's innovative dosage manager integrates digital technologies with conventional drug treatments, positioning it to make a meaningful impact in personalized medicine.
Mimbly
Venture Round in 2020
Mimbly is a company focused on sustainability through innovative water-saving and microplastic-capturing solutions. It manufactures a system designed for laundry applications that recycles water in washing processes. This system connects to a washing machine via a water intake valve, where it tracks, analyzes, and purifies water during each cycle, allowing for its reuse. Mimbly's technology enables professional laundry facilities to adopt more sustainable practices, significantly conserving water, reducing microplastic pollution, and lowering CO2 emissions.
Recycla
Venture Round in 2018
Recycla is a recycling and waste management company that operates a marketplace platform designed to facilitate environmentally efficient recycling solutions. The platform connects users with quality-assured recycling companies, allowing individuals and organizations to easily find suitable partners for their recycling needs, whether at home, in businesses, or within tenant-owner associations. By providing a database of approved companies, Recycla enables users to efficiently match their specific recycling or waste management requests with the right service providers in their geographic area, promoting sustainable practices and cost-effective solutions in the recycling industry.
Cereno Scientific
Seed Round in 2012
Cereno Scientific AB is focused on developing innovative treatments for patients at increased risk of blood clotting, leveraging its patented research on epigenetic modulation through histone deacetylase inhibition (HDACi). The company's lead program, CS1, is a phase two dual-acting antithrombotic drug designed to prevent venous thrombosis and stroke in individuals with atrial fibrillation. In addition to its work on cardiovascular conditions, Cereno Scientific is exploring the therapeutic potential of its technologies for rare diseases associated with pulmonary fibrosis, thrombosis, inflammation, and high blood pressure in the pulmonary circulation system. By normalizing the body’s defense mechanisms against blood clots, Cereno aims to address significant complications in cardiovascular health.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.